Skip to main content

Table 1 Clinical characteristics of four RNA-subtypes

From: Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

 

RNA subtype

C1

(n = 13, 12.7%)

Inflammatory

C2

(n = 45, 44.1%)

EMT

C3

(n = 19, 18.6%)

Stemness

C4

(n = 25, 24.5%)

EGFR-dominant

Pa

Overall Survival b

HR (95% CI)

0.68 (0.34-1.36)

0.92 (0.60-1.42)

6.77 (3.73-12.27)

0.59 (0.35-0.97)

< 0.001

OS (month, median)

22.8

23.0

4.2

36.7

Progression-free Survival b

HR (95% CI)

0.79 (0.37-1.66)

1.41 (0.87-2.28)

2.76 (1.35-5.61)

0.53 (0.31-0.91)

0.020

PFS (month, median)

3.90

2.20

2.15

5.50

Smoking

Pack (year, median)

9.00

0.20

29.00

0.00

0.176

Sex

Male (n = 57, 55.9%)

7 (6.9%)

23 (22.6%)

17 (16.7%)

10 (9.8%)

0.009

Female (n = 45, 44.1%)

6 (5.9%)

22 (21.6%)

2 (2.0%)

15 (14.7%)

Cancer Type

SCLC (n = 6)

0 (0.0%)

2 (2.0%)

4 (3.9%)

0 (0.0%)

0.015

NSCLC (n = 96)

13 (12.8%)

43 (42.2%)

15 (14.7%)

25 (24.5%)

Sample timing

Baseline (n = 31)

5 (4.9%)

13 (12.7%)

9 (8.8%)

4 (3.9%)

0.135

Post (n = 71)

8 (7.8%)

32 (31.4%)

10 (9.8%)

21 (20.6%)

EGFR-TKI therapy group

Sample size (n = 27)

2 (7.4%)

15 (55.6%)

0 (0.0%)

10 (37.0%)

0.038

BASELINE (n = 9)

1 (3.7%)

5 (18.5%)

0 (0.0%)

3 (11.1%)

POST1 (n = 7)

0 (0.0%)

3 (11.1%)

0 (0.0%)

4 (14.8%)

POST2 (n = 4)

0 (0.0%)

1 (3.7%)

0 (0.0%)

3 (11.1%)

POST3 (n = 7)

1 (3.7%)

6 (22.2%)

0 (0.0%)

0 (0.0%)

Target-seq

Sample size (n = 98)

13 (13.3%)

43 (43.9%)

17 (17.3%)

25 (25.5)

 

TP53-mutation

Non-hotspot (n = 42)

4 (4.1%)

9 (9.2%)

8 (8.2%)

21 (21%)

< 0.001

Hotspot (n = 6)

1 (1.0%)

2 (2.0%)

3 (3.1%)

0 (0.0%)

Wild-type (n = 50)

8 (8.2%)

32 (33%)

6 (6.1%)

4 (4.1%)

EGFR-mutation

Target (n = 20)

3 (3.1%)

6 (6.1%)

2 (2.0%)

9 (9.2%)

0.258

NOSaq (n = 2)

0 (0.0%)

2 (2.0%)

0 (0.0%)

0 (0.0%)

T790Maq (n = 3)

0 (0.0%)

1 (1.0%)

0 (0.0%)

2 (2.0%)

NOS (n = 5)

0 (0.0%)

3 (3.1%)

2 (2.0%)

0 (0.0%)

Wild-type (n = 68)

10 (10.2%)

31 (31.6%)

13 (13.3%)

14 (14.3%)

  1. aP-values were acquired from chi-square (categorical variables), ANOVA (quantitative variables), and log-rank (survival variables) tests
  2. bHR Hazard ratio, CI Confidence interval, OS Overall survival, PFS Progression-free survival
  3. c Responder is complete or partial response, and non-responder is stable or progressive disease